Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

28.14 +1.96 (+7.51%)
Streaming Delayed Price Updated: 11:12 AM EST, Nov 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zymeworks Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Company to participate in investor conferences in July and August 
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
From Zymeworks Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.